Development of progressive hearing loss and tinnitus in a patient with myasthenia gravis: an overlooked comorbidity?
Gilhus N E. Eculizumab: a treatment option for myasthenia gravis? Lancet Neurol 2017; 16: 947 –48—The original title of this comment was “Eculizumab: a treatment option for mysthenia gravis?”. This title has been corrected to “Eculizumab: a treatment option for myasthenia gravis?”. This correction has been made to the online version as of Dec 15, 2017.
Publication date: December 2017 Source:The Lancet Neurology, Volume 16, Issue 12 Author(s): Nils Erik Gilhus
We report on a 51-year-old, male rebreather diver who suffered loss of consciousness and cardiovascular collapse within minutes of a 30-metre deep dive at a remote Micronesian dive site. Recompression treatment did not start for six days for reasons to be presented, during which time he remained deeply comatose, cardiovascularly unstable and intubated on ventilator support. Despite this, following aggressive hyperbaric treatment over many days he made a functional recovery. At one year post injury, he is leading a functional life but has not returned to his previous occupation as a diver and suffers from moderately severe ...
CONCLUSION: The latter process may be induced by transient auditory events in normal processing but it persists in tinnitus, driven by phantom signals from the auditory pathway. Several tinnitus therapies attempt to suppress tinnitus through plasticity, but repeated sessions will likely be needed to prevent tinnitus activity from returning owing to deafferentation as its initiating condition. PMID: 29234817 [PubMed - as supplied by publisher]
CONCLUSIONS Low-grade malignant ELSTs occur most frequently on the left side, with a female preponderance. The disease progressed slowly, with no death, and but relapse in two patients in this series. These tumors are often misdiagnosed.
Conditions: Stent Stenosis; Intracranial Hypertension; Headache; Tinnitus; Papilledema; Visual Impairment Interventions: Procedure: Venous stenting for internal jugular vein stenosis; Procedure: One-month routine medical treatment followed by venous stenting for internal jugular vein stenosis Sponsor: Capital Medical University Not yet recruiting
Conclusions:To our knowledge, this is the first reported case of unicentric CD with FDCS presenting with PTC and MG. A potential unifying pathophysiology could involve the elevation of interleukin-6, which has been previously described to contribute to lymphoproliferation associated with cases of CD and CD with MG. Elevated IL-6 levels in serum and CSF have been noted in PTC, which may be a linking factor to CD or an epiphenomenon.Disclosure: Dr. Fein has nothing to disclose. Dr. Trejo Bittar has nothing to disclose. Dr. Shende has nothing to disclose. Dr. Scalzetti has nothing to disclose. Dr. Ko has nothing to disclose.